Immunosuppression in renal transplantation and dyslipidemia, which factors should be considered?
作者信息
De Giorgi Alfredo, Fabbian Fabio
机构信息
Department of Medical Science, University of Ferrara, University Hospital S. Anna, Ferrara, Italy.
出版信息
Nephrourol Mon. 2013 Nov;5(5):1008-9. doi: 10.5812/numonthly.14189. Epub 2013 Nov 13.
Abstract
摘要
相似文献
1
Immunosuppression in renal transplantation and dyslipidemia, which factors should be considered?
Nephrourol Mon. 2013 Nov;5(5):1008-9. doi: 10.5812/numonthly.14189. Epub 2013 Nov 13.
2
Dyslipidemia and its management after renal transplantation.
J Nephrol. 2001 Nov-Dec;14 Suppl 4:S81-8.
3
Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
Ann Transplant. 2008;13(2):46-53.
4
Liver transplantation: role of immunosuppression, renal dysfunction and cardiovascular risk factors.
Minerva Chir. 2012 Feb;67(1):1-13.
5
Dyslipidemia treatment and cardiovascular disease in the renal patient.
Curr Pharm Des. 2011;17(9):894-907. doi: 10.2174/138161211795428867.
6
Dyslipidemia following kidney transplantation: diagnosis and treatment.
Curr Diab Rep. 2009 Aug;9(4):305-11. doi: 10.1007/s11892-009-0047-0.
7
[The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
G Ital Nefrol. 2008 Nov-Dec;25 Suppl 44:S11-4.
8
Mechanisms and treatment of dyslipidemia of renal diseases.
Curr Opin Nephrol Hypertens. 1993 Sep;2(5):784-90. doi: 10.1097/00041552-199309000-00012.
9
Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation.
Dis Markers. 2015;2015:179434. doi: 10.1155/2015/179434. Epub 2015 Apr 6.
10
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Prev Cardiol. 2005 Fall;8(4):244-9. doi: 10.1111/j.0197-3118.2005.04078.x.
引用本文的文献
1
Immunosuppressive Agents-Effects on the Cardiovascular System and Selected Metabolic Aspects: A Review.
J Clin Med. 2023 Nov 5;12(21):6935. doi: 10.3390/jcm12216935.
本文引用的文献
1
Dyslipidemia after kidney transplantation and correlation with cyclosporine level.
Nephrourol Mon. 2013 Jul 1;5(3):831-4. doi: 10.5812/numonthly.11890. Epub 2013 Jun 14.
2
US Renal Data System 2012 Annual Data Report.
Am J Kidney Dis. 2013 Jan;61(1 Suppl 1):A7, e1-476. doi: 10.1053/j.ajkd.2012.11.031.
3
Evidence-based statin prescription for cardiovascular protection in renal impairment.
Clin Exp Nephrol. 2011 Aug;15(4):456-63. doi: 10.1007/s10157-011-0454-9. Epub 2011 May 10.
4
Risk factors for metabolic syndrome in stable Italian renal transplant patients.
Clin Exp Nephrol. 2011 Aug;15(4):560-6. doi: 10.1007/s10157-011-0422-4. Epub 2011 Mar 1.
5
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
Vasc Health Risk Manag. 2007;3(6):877-86.
6
Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats.
Dig Dis Sci. 2004 Jan;49(1):30-7. doi: 10.1023/b:ddas.0000011598.15105.58.
7
ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease.
Kidney Int. 1996 Aug;50(2):538-42. doi: 10.1038/ki.1996.346.
8
Relation of cyclosporine blood levels to adverse effects on lipoproteins.
Transplantation. 1994 May 27;57(10):1479-83.
9
Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia.
Am J Kidney Dis. 1991 Sep;18(3):353-8. doi: 10.1016/s0272-6386(12)80095-3.
10
The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression.
J Thorac Cardiovasc Surg. 1992 Aug;104(2):241-7.
Zotero 插件